Therapeutic Monitoring of Psychotropic Drugs: An Outline of the AGNP-TDM Expert Group Consensus Guideline

Therapeutic Drug Monitoring

Volumn 26, Issue 2, 2004, Pages 167-170

  Baumann, Pierre ^a   Hiemke, C ^b   Ulrich, S ^c   Gaertner, I ^d   Rao, M L ^e   Eckermann, G ^f   Gerlach, M ^g   Kuss, H J ^h   Laux, G ⁱ   Muller Oerlinghausen B ^j   Riederer, P ^g   Zernig, G ^k  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c Esparma GmbH   (Germany)

^d Psychiatric Hospital   (Germany)

^e UNIVERSITY OF BONN   (Germany)

^f Bezirkskrankenhaus Kaufbeuren   (Germany)

^g UNIVERSITY OF WÜRZBURG   (Germany)

^h UNIVERSITY OF MUNICH   (Germany)

ⁱ Bezirksklinikuna Gabersee ^*  (Germany)

^j Drug Commission of the German Medical Association   (Germany)

^k University of   (Austria)

more..

Author keywords

Consensus statement; Psychotropic drugs; Therapeutic drug monitoring

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; OPIATE DERIVATIVE; PSYCHOTROPIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ANALYTIC METHOD; CONFERENCE PAPER; DRUG METABOLISM; DRUG MONITORING; HUMAN; LABORATORY TEST; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; TREATMENT INDICATION;

DRUG MONITORING; HUMANS; PRACTICE GUIDELINES; PSYCHOTROPIC DRUGS; REFERENCE VALUES;

EID: 4444275473     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200404000-00014     Document Type: Conference Paper

References (10)

1. Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand. 2001;104:173-192.
2. Dahl ML, Sjöqvist F. Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics. Ther Drug Monit. 2000;22:114-117.
3. Task Force on the Use of Laboratory Tests in Psychiatry. Tricyclic antidepressants-blood level measurements and clinical outcome: an APA task force report. Am JPsychiatry. 1985;142:155-162.
4. Laux G, Riederer P, eds. Plasmaspiegelbestimmung von Psychopharmaka: Therapeutisches Drug-Monitoring. Versuch einer ersten Standort-bestimmung. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 1992.
5. Wilson JF. Survey of reference ranges and clinical measurements for psychoactive drugs in serum. Ther Drug Monit. 2003;25:243-247.
6. Meijer WEE, Bouvy ML, Heerdink ER, et al. Spontaneous lapses in dosing during chronic treatment with selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;179:519-522.
7. Ulrich S, Schrödter I, Partscht G, et al. Therapeutisches Drug-Monitoring von Psychopharmaka: Eine allgemeine Einführung. Psychopharmakotherapie. 2000;7:2-14.
8. Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000;85:11-28.
9. Rasmussen BB, Brosen K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000;22:143-154.
10. Eap CB, Bourquin M, Martin J, et al. Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. Drug Alcohol Depend. 2000;61:47-54.